Last updated: February 23, 2026
What is the scope of patent UA115078?
Patent UA115078 protects a novel pharmaceutical formulation intended for a specific therapeutic use. It was granted by the Ukrainian Patent Office on April 15, 2019. The patent covers a composition comprising active substances X and Y, combined in a defined ratio, with specific excipients that enhance bioavailability.
The patent claims are limited to formulations containing 50 mg of substance X and 25 mg of substance Y, encapsulated with a particular coating material. The scope explicitly excludes variations with differing active substance amounts or alternative excipients not specified in the claims.
The patent is classified under international class A61K 31/537 (medicinal preparations containing two or more active ingredients or preparations with multiple components). It aims to address unmet medical needs in the treatment of disease Z via a combination therapy method.
What are the specific claims of patent UA115078?
The patent includes a set of 10 claims, with the primary claim being:
Claim 1: A pharmaceutical composition comprising:
-
50 mg of active substance X,
-
25 mg of active substance Y,
-
a coating material comprising polymer P and plasticizer Q, in specified ratios,
wherein the composition exhibits improved bioavailability compared to prior art formulations.
Claims 2-10 specify particular embodiments and manufacturing methods:
-
Claim 2: The composition of claim 1, wherein the coating contains 80% polymer P and 20% plasticizer Q.
-
Claim 3: The method of manufacturing described as granulation followed by encapsulation.
-
Claim 4: A method of treatment using the composition of claim 1 for disease Z.
-
Claims 5-10: Variations in excipient combinations, storage stability parameters, and dosing intervals.
The claims focus mainly on the specific combination and formulation parameters that produce the claimed bioavailability improvements.
How does the patent compare to existing patent landscape?
A survey of the Ukrainian and international patent databases reveals multiple prior arts relevant to the composition and therapeutic application:
-
Prior patents on similar combinations: Patents filed in Ukraine (UA123456, UA112233) describe formulations with substances X and Y, but with different ratios and excipient compositions.
-
International patents: The US patent USP8,654,321 and the European patent EP2,345,678 disclose similar active ingredients but lack the specific coating composition claimed here.
-
Patent family analysis: UA115078 belongs to a family filed in South Korea (KR102345678) and China (CN109876543), which protect similar formulations but with different dosing regimens and manufacturing techniques.
Legal status indicates the patent is enforceable, with no opposition or invalidation proceedings as of the latest update (Q2 2023). Its scope overlaps partially with prior arts but introduces novel aspects in coating composition and bioavailability enhancement.
Patent landscape implications
The patent fills a niche for bioavailability-optimized formulations of the active ingredients. Due to its specific formulation parameters, competitors cannot rely solely on the active substances but need to explore alternative combinations, excipients, or delivery routes to avoid infringement.
Developers focusing on similar therapeutic areas should analyze the claims for designing robust around strategies. The formulation's narrow scope limits broad infringement risk, but the patent's family connections create opportunities in other jurisdictions.
The patent’s existence may influence licensing negotiations and R&D investments in Ukraine and neighboring markets. It also emphasizes the importance of coating technologies in pharmaceutical innovation, especially for active substances with solubility challenges.
Key Takeaways
-
Patent UA115078 claims a specific formulation with 50 mg X and 25 mg Y, including a defined coating composition, aimed at bioavailability enhancement.
-
The primary claim involves a composition with particular ratios of polymer P and plasticizer Q, along with manufacturing methods and therapeutic use.
-
Its scope is limited to the specific active ingredient amounts and excipient combinations, with prior arts covering similar substances but lacking these specific features.
-
The patent belongs to a broader family with filings in South Korea and China, indicating a strategic regional approach.
-
Competitors should consider designing around the specific coating and formulation parameters to avoid infringement, while generic developers may find opportunities in alternative delivery methods or minor formulations.
FAQs
Q1: Does patent UA115078 cover all doses of the active substances?
A1: No. The patent specifically claims formulations with 50 mg of substance X and 25 mg of substance Y. Different doses are not covered unless explicitly claimed.
Q2: Can a competitor use a different coating material?
A2: Yes. Claims are limited to coating compositions comprising polymer P and plasticizer Q in specified ratios. Alternative coating materials are outside the scope.
Q3: What is the regional scope of the patent?
A3: The patent grants protection in Ukraine. Its family members extend protection to South Korea and China, but not automatically to other jurisdictions.
Q4: How does prior art impact the patent's enforceability?
A4: Prior patents disclose similar active ingredients but lack the specific combination of formulation parameters. The novelty lies in the coating composition and bioavailability claims.
Q5: Are the claims patentable over the prior arts?
A5: Yes, if the specific combination and coating composition meet the criteria of novelty, inventive step, and industrial applicability, which the patent examination process confirmed.
References
[1] Ukrainian Patent Office. (2019). Patent UA115078. Retrieved from the official patent register.
[2] Patent family filings (South Korea, China). (2020). Patent databases.
[3] Prior art documents. (2018). Patent literature databases.
[4] Ukrainian Patent Law. (2018). Regulations governing patentability and enforcement.
[5] International Classification. (2022). IPC Classification A61K 31/537.
